Investigational drug · Phase 3
VT3989
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "VT3989"
First trial start
2021
Mar 24, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VT3989", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pleural Mesothelioma
- Mesothelioma
- Solid Tumor, Adult
- NSCLC
- Non-Pleural Mesothelioma
- Non Small Cell Lung Cancer
- Epithelioid Hemangioendothelioma (EHE)
- Adenoma
- Neoplasms
- Neoplasms, Glandular and Epithelial
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "VT3989" as an intervention, largest first.
Vivace Therapeutics, IncIndustry
NCT04665206 · 474 participants (planned) · Start Mar 24, 2021 · Primary completion Nov 2, 2029
Drug: VT3989; Nivolumab & Ipilimumab and 2 more · For: Solid Tumor, Adult; Mesothelioma; NSCLC and 9 more
Sites: San Francisco, California; Chicago, Illinois; Boston, Massachusetts · 12 sites in all
- A Phase 3 Trial in Advanced Epithelioid MesotheliomaPivotal-lookingNot yet recruiting
Vivace Therapeutics, IncIndustry
NCT07824986 · 350 participants (planned) · Start Dec 1, 2026 · Primary completion May 1, 2028
Drug: VT3989; gemcitabine and 1 more · For: Pleural Mesothelioma; Mesothelioma
Newest research
PubMed records naming it or its code names, newest first.
- YAP-TEAD-driven CPA4 promotes NF2-deficient meningioma growth.
Mineji K, Petrosky K, Otsuji R, et al. · bioRxiv 2026
- Pharmacologic Inhibition of YAP/TEAD and Development of New Chorioretinal Atrophy.
Kozek LK, Bleicher I, Lu ES, et al. · JAMA Ophthalmol 2026
- YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.
Yap TA, Kwiatkowski DJ, Dagogo-Jack I, et al. · Nat Med 2025
- Variable Schwann cell merlin inactivation is targetable with TEAD1 inhibition in schwannomas.
Laws MT, Bhatt D, Mandal D, et al. · bioRxiv 2025
- Hippo/YAP signaling pathway in colorectal cancer: regulatory mechanisms and potential drug exploration.
Zhang L, Zhang F, Liang H, et al. · Front Oncol 2025
- [Advances in Targeted Therapy for Malignant Pleural Mesothelioma].
Fu F, Zhang Y, Shen H · Zhongguo Fei Ai Za Zhi 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.